Daily Sepsis Research Analysis
Large-scale observational studies highlight shifting sepsis epidemiology and phenotypes: community-onset Klebsiella pneumoniae bloodstream infections have risen markedly over two decades, acute kidney injury in Staphylococcus aureus bacteremia strongly predicts 30-day mortality with distinct early/late patterns, and immune-based clustering reveals prognostically distinct sepsis subtypes. These findings can guide surveillance, dosing and monitoring strategies, and precision risk stratification.
Summary
Large-scale observational studies highlight shifting sepsis epidemiology and phenotypes: community-onset Klebsiella pneumoniae bloodstream infections have risen markedly over two decades, acute kidney injury in Staphylococcus aureus bacteremia strongly predicts 30-day mortality with distinct early/late patterns, and immune-based clustering reveals prognostically distinct sepsis subtypes. These findings can guide surveillance, dosing and monitoring strategies, and precision risk stratification.
Research Themes
- Rising community-onset AMR Gram-negative bloodstream infections
- Organ dysfunction phenotyping in sepsis (AKI timing and outcomes)
- Immune subtyping for precision risk stratification in sepsis
Selected Articles
1. Klebsiella pneumoniae species complex bloodstream infection in adult patients: changing epidemiology and determinants of poor outcomes.
In a 20-year, population-based cohort from Queensland, K. pneumoniae bloodstream infection incidence more than doubled, driven by community-onset cases, while third-generation cephalosporin resistance increased annually yet was not independently associated with mortality. Mortality was 11.5% at 30 days, with lower respiratory tract source conferring higher risk and urinary tract source lower risk.
Impact: This large, population-level analysis quantifies a major shift toward community-onset Kp-BSI and disentangles antimicrobial resistance from mortality risk, informing surveillance and empiric therapy policies.
Clinical Implications: Expect rising community-onset Kp-BSI; tailor empiric Gram-negative coverage to local epidemiology and source of infection rather than 3GC-R status alone. Prioritize prevention in community settings and consider heightened vigilance for lower respiratory tract sources.
Key Findings
- Incidence of Kp-BSI more than doubled from 5.8 to 12.2 per 100,000 over 20 years (∼4.5% annual rise).
- Third-generation cephalosporin-resistant Kp-BSI increased nearly 10% per year but was not associated with 30-day mortality (aHR 1.08, 95% CI 0.76-1.50).
- Overall 30-day mortality was 11.5%; lower respiratory tract source increased death risk (aHR 1.68), while urinary tract source decreased it (aHR 0.48).
- Hospital-onset proportion decreased from 49.1% to 35.0%, indicating a shift toward community-onset disease.
Methodological Strengths
- Population-based, 20-year cohort with statewide linkage capturing 7,496 episodes.
- Use of adjusted hazard models to assess source-specific mortality risks and resistance impact.
Limitations
- Retrospective design with potential residual confounding and changes in practice over time.
- Limited generalizability outside Queensland; lack of pathogen genomic data to explain community surge.
Future Directions: Integrate genomic epidemiology to trace community-onset drivers, evaluate targeted prevention strategies, and refine empiric treatment pathways based on source-specific risks.
PURPOSE: Klebsiella pneumoniae is a common cause of hospital- and community-acquired infection and can readily acquire multiple antimicrobial resistance determinants leading to poor health outcomes. We define the contemporary burden of disease, risk factors for antimicrobial resistance, and poor health outcomes for patients with K. pneumoniae bloodstream infection (Kp-BSI). METHODS: All blood cultures with growth of K. pneumoniae species complex among residents of Queensland, Australia (population ≈ 5 million) who received care through a public hospital were identified over a 20-year period. Clinical, microbiological and outcome information was obtained from state-wide databases. RESULTS: A total of 6, 988 patients (7, 496 episodes) with incident Kp-BSI were identified. Incidence rate more than doubled from 5.8 cases to 12.2 cases per 100,000 population over the study period (4.5% rise per year). 258 (3.4%) episodes involved isolates resistant to third-generation cephalosporins (3GC-R). 3GC-R Kp-BSI crude incidence rate increased almost 10% each year. The proportion of hospital-onset episodes reduced from 49.1 to 35.0%. Of all Kp-BSI episodes, 864 (11.5%) died within 30-days. A lower respiratory tract source was associated with a high risk of death (aHR 1.68, 95% CI 1.30-2.16) while a urinary tract source a lower risk (aHR 0.48, 95% CI 0.35-0.66). 3GC-R Kp-BSI was not related to death (aHR 1.08, 95% CI 0.76-1.50). CONCLUSION: A rising burden of both Kp-BSI and 3GC-R blood isolates in a previous low-prevalence setting is concerning. A significant rise in community-onset Kp-BSI over the 20-year period was noteworthy and requires further evaluation. 3GC-R status was not associated with mortality.
2. Immune Subtypes in Sepsis: A Retrospective Cohort Study Utilizing Clustering Methodology.
Using K-means clustering of lymphocyte subsets, cytokines, and inflammatory markers in 236 sepsis patients, three immune subtypes were identified. The high-inflammation/immune-suppressed subtype had dramatically worse 28-day survival (HR 21.65 vs high-activation subtype), supporting immune-phenotype-driven risk stratification.
Impact: Introduces clinically meaningful immune subtypes with striking prognostic separation, advancing precision sepsis research and potential for targeted immunomodulation.
Clinical Implications: Consider early immune profiling to identify high-inflammation/immune-suppressed patients at extreme risk who may benefit from tailored monitoring and potential immunomodulatory strategies.
Key Findings
- Three immune subtypes were delineated: high activation, moderate activation, and high inflammation with immune suppression.
- The high inflammation/immune-suppressed subtype had markedly higher 28-day mortality (HR 21.65; 95% CI 7.46–62.87; p < 0.001).
- Kaplan–Meier curves showed highly significant survival separation among clusters (p < 0.0001).
Methodological Strengths
- Comprehensive immune profiling with lymphocyte subsets and cytokines.
- Unsupervised clustering with survival validation (HR and Kaplan–Meier analyses).
Limitations
- Single-center retrospective cohort with modest sample size (n=236).
- Potential overfitting and lack of external validation; timing of sampling relative to illness course may vary.
Future Directions: Prospectively validate immune subtypes across centers, standardize sampling windows, and test immunomodulatory interventions tailored to high-risk phenotypes.
BACKGROUND: Sepsis is a heterogeneous clinical syndrome. Identifying distinct clinical phenotypes may enable more targeted therapeutic interventions and improve patient care. OBJECTIVE: This study aims to use clustering analysis techniques to identify different immune subtypes in sepsis patients and explore their clinical relevance and prognosis. METHODS: The study included 236 patients from the EICU at Shanghai Tenth People's Hospital, who met the Sepsis 3.0 diagnostic criteria. Blood samples were collected to measure lymphocyte subsets and cytokine levels, along with demographic and clinical data. K-means clustering analysis was used to categorize patients into three groups based on immune and inflammatory markers. RESULTS: Three immune subtypes were identified: the high immune activation subtype (Cluster 1), characterized by high levels of CRP and WBC, high levels of T cells, NK cells, and B cells, and low levels of IL-6, IL-8, and IL-10; the moderate immune activation subtype (Cluster 2), characterized by moderate levels of CRP, WBC, T cells, NK cells, B cells, IL-6, IL-8, and IL-10; and the high inflammation and immune suppression subtype (Cluster 3), characterized by very high levels of IL-6, IL-8, and IL-10, low levels of T cells, NK cells, and B cells, and relatively lower CRP levels. Patients in Cluster 3 had a significantly increased 28-day mortality risk compared to those in Cluster 1 (HR = 21.65, 95% CI: 7.46-62.87, p < 0.001). Kaplan-Meier survival curves showed the lowest survival rates for Cluster 3 and the highest for Cluster 1, with the differences among the three groups being highly statistically significant (p < 0.0001). CONCLUSION: This study identified three immune subtypes of sepsis that are significantly associated with clinical outcomes. These findings provide evidence for personalized treatment strategies to improve patient outcomes.
3. Not "a cute" complication: phenotypic analysis of acute kidney injury in Staphylococcus aureus bacteraemia.
Among 2,734 adults with S. aureus bacteremia, KDIGO-defined AKI occurred in 46% and was associated with a 3.8-fold higher 30-day mortality. Early AKI resolved more frequently than late AKI, suggesting phenotype-based implications for monitoring and timing of antimicrobial dose adjustments.
Impact: Defines high AKI burden and distinct temporal phenotypes linked to mortality in SAB, informing renal risk stratification and stewardship decisions.
Clinical Implications: Implement early and ongoing renal monitoring in SAB; recognize late AKI as a high-risk phenotype and consider delaying antimicrobial dose reduction until renal recovery is clear.
Key Findings
- AKI occurred in 46% (1255/2734) of SAB patients and was associated with higher 30-day mortality (OR 3.81; 95% CI 3.08–4.73; p ≤ 0.001).
- Overall 30-day mortality was 18% (492/2734).
- Early AKI resolved within 14 days in 62% (173/277) vs 23% (101/435) for late AKI (p ≤ 0.001), indicating distinct temporal phenotypes.
Methodological Strengths
- Large, long-term cohort with standardized KDIGO AKI definitions and temporal phenotyping.
- Robust statistical association with clinically meaningful endpoints (30-day mortality).
Limitations
- Retrospective design susceptible to residual confounding and practice changes over 25 years.
- Potential misclassification of baseline creatinine and limited external generalizability.
Future Directions: Prospective validation of early/late AKI phenotypes in SAB, integration with stewardship protocols for dose adjustment timing, and exploration of mechanistic drivers of late AKI.
OBJECTIVES: In this large retrospective cohort analysis, we aimed to determine the incidence of Kidney Disease Improving Global Outcomes (KDIGO)-defined acute kidney injury (AKI) within 14 days in patients with Staphylococcus aureus bacteraemia (SAB), and the association of AKI with 30-day mortality. METHODS: A retrospective cohort study of adults with SAB between 1998 to 2023 admitted to a large regional Australian health service. Baseline creatinine was the lowest serum creatinine concentration in the 365 days before the day of index blood culture collection and AKI was defined and staged using the KGIDO criteria. AKIs were classified as early (within 48 hours of index blood culture) or late (48 hours to 14 days after index blood culture). RESULTS: In those with SAB, AKI occurred in 46% (1255/2734) and was significantly linked to all-cause 30-day mortality (for patients with AKI, 354 died, 901 survived; without AKI 138 died and 1341 survived; OR, 3.81; 95% CI, 3.08-4.73; p ≤ 0.001). Overall 30-day mortality was 18% (492/2734). AKI resolution within 14 days occurred in 173/277 (62%) of those with an early AKI only, and in 101/435 (23%) of those with a late AKI only (p ≤ 0.001). DISCUSSION: AKI is a frequent complication of SAB and is associated with 30-day mortality. Some AKI phenotypes have rapid resolution, which supports the consideration of delayed antimicrobial dose reduction.